Effect of Mode of Femoral Nerve Analgesia on Quadriceps Muscle Strength

Overview

Quadriceps muscle strength is an important determinant of quality of recovery in elderly patients after total knee arthroplasty. We try to compare the quadriceps muscle strength change between 0.2 % ropivacaine continuous fixed femoral infusion and patient controlled femoral analgesia group.

Full Title of Study: “Effect of Continuous Femoral Analgesia on Quadriceps Muscle Strength-0.2% Ropivacaine Continuous Infusion Versus Patient Controlled Femoral Analgesia”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2015

Detailed Description

Continuous femoral nerve analgesia technique is relatively safe, can be easily trained, and reduces significantly intravenous opioid consumption. These favorable features make it standard treatment option for postoperative knee pain. However, direct perineural local anesthetic effect is not only confined into pain fiber, but, the other sensory and motor nerve fibers. Therefore, unwanted motor weakness is accompanied. Quadriceps muscle strength, which is important determinant of physical function after knee arthroplasty, can be influenced in continuous femoral nerve block. Various local anesthetic infusion techniques have been suggested to minimize the change of quadriceps muscle strength. Decreasing local anesthetic concentrations affect not only degree of muscle weakness, but also reduces the quality of pain control. Different anatomic location of catheter tip, considering motor fiber in posterior part of femoral nerve, could not reduce motor weakness. In a study with continuous popliteal-sciatic nerve blocks after hallux valgus repair, repeated bolus administration seems to be more effective method for pain control without concurrent motor impairment. However, another study with continuous femoral nerve block in healthy volunteers, hourly repeated bolus dose of 5 ml of 0.1% ropivacaine failed to spare motor block. Previously, our institution standard technique is fixed continuous infusion of 0.2% ropivacaine and concomitant intravenous patient controlled fentanyl. Because physical therapy of our institution, usually starts with the 2nd day of operation, so, we assume that continuous fixed infusion may result in more drug accumulation near nerve fiber. So, patient controlled mode of femoral analgesia could be better choice for initiation of physical therapy. At the same time, comparison between patient controlled analgesia and continuous infusion is not fully elucidated until recently. Therefore, in this study, we try to compare quadriceps muscle strength change between continuous infusion and patient controlled femoral analgesia in patients undergoing total knee replacement arthroplasty. Secondary outcomes include sensory effect in femoral nerve distribution, pain scores, iv fentanyl consumption, and other adverse effects.

Interventions

  • Drug: ropivacaine
    • Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery

Arms, Groups and Cohorts

  • Placebo Comparator: ropivacaine continuous mode
    • 0.2% ropivacaine 8 ml/hr through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
  • Active Comparator: ropivacaine patient controlled mode
    • 0.2% ropivacaine patient controlled mode, basal rate 4 ml/hr, bolus 4 ml, lockout 60 minutes through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl

Clinical Trial Outcome Measures

Primary Measures

  • Change of quadriceps muscle strength
    • Time Frame: Baseline, Postoperative 2nd day
    • maximum voluntary isometric contraction of quadriceps femoris with hand held manometry

Secondary Measures

  • sensory changes in femoral nerve distribution
    • Time Frame: postoperative 2 day
    • tolerance to transcutaneous electrical stimulation
  • pain scores
    • Time Frame: postoperative 1 day
    • verbal numeric pain scale (0-100) resting/dynamic
  • pain scores
    • Time Frame: postoperative 2 day
    • verbal numeric pain scale (0-100) resting/dynamic
  • intravenous fentanyl consumption
    • Time Frame: postoperative 2 day
    • cumulative fentanyl consumption on postoperative 2 day

Participating in This Clinical Trial

Inclusion Criteria

  • > 21, or < 80 years old- men and women – primary, unilateral total knee replacement surgery – spinal anesthesia Exclusion Criteria:

  • general anesthesia – secondary knee replacement surgery – patient refusal for continuous femoral nerve analgesia technique – abnormal coagulation profile, e.g. Prothrombin time international normalized ratio > 1.5, activated partial thrombin time > 50 sec – within 5 days after termination oral antiplatelet agent – Body mass index>45 – impaired renal function – infection near femoral area – previous injury near femoral area – neurologic dysfunction in lower limb – previous adverse drug reaction for local anesthetics – American society of anesthesiologists (ASA) class III, iV or V

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Seoul National University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Hae Wone Chang, Clinical Associate Professor – Seoul National University Hospital
  • Overall Official(s)
    • Hae Wone Chang, M.D., Principal Investigator, Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital
  • Overall Contact(s)
    • Hae Wone Chang, M.D, 82-031-787-7499, chelenh@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.